# PERCI- Medium Cut Off (MCO)

> **NCT02084381** · NA · COMPLETED · sponsor: **Vantive Health LLC** · enrollment: 50 (actual)

## Conditions studied

- Chronic Kidney Failure
- Chronic Inflammation

## Interventions

- **DEVICE:** MCO-Ci 400
- **DEVICE:** Revaclear 400

## Key facts

- **NCT ID:** NCT02084381
- **Lead sponsor:** Vantive Health LLC
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-07
- **Final completion:** 2015-02
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-03-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02084381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02084381, "PERCI- Medium Cut Off (MCO)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02084381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*